Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Varsha Gandhi, PhD, on Ibrutinib

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Apr

Today In Oncology

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Varsha Gandhi, PhD, on Ibrutinib

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Is Standard of Care Optimal for the Individual Patient?

LuPSMA-617 and Pembrolizumab in mCRPC

ASH-ISTH Create Guidelines for Pediatric VTE Prophylaxis

Asbestos-Free Talc Not Associated With Increased Risk for Respiratory Cancers

New Molecular-Based Model for Classification and Risk in Chronic Myelomonocytic Leukemia